This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gu, Z.
Right arrow Articles by Rando, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gu, Z.
Right arrow Articles by Rando, R. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2376-2382, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Mechanism of Action and In Vitro Activity of 1',3'-Dioxolanylpurine Nucleoside Analogues against Sensitive and Drug-Resistant Human Immunodeficiency Virus Type 1 Variants

Zhengxian Gu,1,* Mark A. Wainberg,2 Nghe Nguyen-Ba,1 Lucille L'Heureux,1 Jean-Marc de Muys,1 Terry L. Bowlin,1 and Robert F. Rando1

BioChem Pharma, Laval, Quebec H7V 4A7,1 and McGill University AIDS Center, Jewish General Hospital, Montreal, Quebec H3T 1E2,2 Canada

Received 9 April 1999/Returned for modification 15 July 1999/Accepted 6 August 1999

(-)-beta -D-1',3'-Dioxolane guanosine (DXG) and 2,6-diaminopurine (DAPD) dioxolanyl nucleoside analogues have been reported to be potent inhibitors of human immunodeficiency virus type 1 (HIV-1). We have recently conducted experiments to more fully characterize their in vitro anti-HIV-1 profiles. Antiviral assays performed in cell culture systems determined that DXG had 50% effective concentrations of 0.046 and 0.085 µM when evaluated against HIV-1IIIB in cord blood mononuclear cells and MT-2 cells, respectively. These values indicate that DXG is approximately equipotent to 2',3'-dideoxy-3'-thiacytidine (3TC) but 5- to 10-fold less potent than 3'-azido-2',3'-dideoxythymidine (AZT) in the two cell systems tested. At the same time, DAPD was approximately 5- to 20-fold less active than DXG in the anti-HIV-1 assays. When recombinant or clinical variants of HIV-1 were used to assess the efficacy of the purine nucleoside analogues against drug-resistant HIV-1, it was observed that AZT-resistant virus remained sensitive to DXG and DAPD. Virus harboring a mutation(s) which conferred decreased sensitivity to 3TC, 2',3'-dideoxyinosine, and 2',3'-dideoxycytidine, such as a 65R, 74V, or 184V mutation in the viral reverse transcriptase (RT), exhibited a two- to fivefold-decreased susceptibility to DXG or DAPD. When nonnucleoside RT inhibitor-resistant and protease inhibitor-resistant viruses were tested, no change in virus sensitivity to DXG or DAPD was observed. In vitro drug combination assays indicated that DXG had synergistic antiviral effects when used in combination with AZT, 3TC, or nevirapine. In cellular toxicity analyses, DXG and DAPD had 50% cytotoxic concentrations of greater than 500 µM when tested in peripheral blood mononuclear cells and a variety of human tumor and normal cell lines. The triphosphate form of DXG competed with the natural nucleotide substrates and acted as a chain terminator of the nascent DNA. These data suggest that DXG triphosphate may be the active intracellular metabolite, consistent with the mechanism by which other nucleoside analogues inhibit HIV-1 replication. Our results suggest that the use of DXG and DAPD as therapeutic agents for HIV-1 infection should be explored.

* Corresponding author. Mailing address: BioChem Pharma, 275 Armand-Frappier Blvd., Laval, Quebec H7V 4A7, Canada. Phone: (450) 978-6210. Fax: (450) 978-7946. E-mail: guz{at}biochempharma.com.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2376-2382, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hurwitz, S. J., Asif, G., Kivel, N. M., Schinazi, R. F. (2008). Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model. Antimicrob. Agents Chemother. 52: 4241-4250 [Abstract] [Full Text]  
  • Menne, S., Asif, G., Narayanasamy, J., Butler, S. D., George, A. L., Hurwitz, S. J., Schinazi, R. F., Chu, C. K., Cote, P. J., Gerin, J. L., Tennant, B. C. (2007). Antiviral Effect of Orally Administered ( )-{beta}-D-2-Aminopurine Dioxolane in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. Antimicrob. Agents Chemother. 51: 3177-3184 [Abstract] [Full Text]  
  • Lennerstrand, J., Chu, C. K., Schinazi, R. F. (2007). Biochemical Studies on the Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to 1-({beta}-D-Dioxolane)Thymine Triphosphate. Antimicrob. Agents Chemother. 51: 2078-2084 [Abstract] [Full Text]  
  • Rando, R. F., Obara, S., Osterling, M. C., Mankowski, M., Miller, S. R., Ferguson, M. L., Krebs, F. C., Wigdahl, B., Labib, M., Kokubo, H. (2006). Critical design features of phenyl carboxylate-containing polymer microbicides.. Antimicrob. Agents Chemother. 50: 3081-3089 [Abstract] [Full Text]  
  • Gu, Z., Allard, B., de Muys, J. M., Lippens, J., Rando, R. F., Nguyen-Ba, N., Ren, C., McKenna, P., Taylor, D. L., Bethell, R. C. (2006). In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection. Antimicrob. Agents Chemother. 50: 625-631 [Abstract] [Full Text]  
  • Borroto-Esoda, K., Myrick, F., Feng, J., Jeffrey, J., Furman, P. (2004). In Vitro Combination of Amdoxovir and the Inosine Monophosphate Dehydrogenase Inhibitors Mycophenolic Acid and Ribavirin Demonstrates Potent Activity against Wild-Type and Drug-Resistant Variants of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 48: 4387-4394 [Abstract] [Full Text]  
  • Tremblay, C. L., Poulin, D. L., Hicks, J. L., Selliah, S., Chamberland, A., Giguel, F., Kollmann, C. S., Chou, T. C., Dong, H., Hirsch, M. S. (2003). Favorable Interactions between Enfuvirtide and 1-{beta}-D-2,6-Diaminopurine Dioxolane In Vitro. Antimicrob. Agents Chemother. 47: 3644-3646 [Abstract] [Full Text]  
  • Jeffrey, J. L., Feng, J. Y., Qi, C. C. R., Anderson, K. S., Furman, P. A. (2003). Dioxolane Guanosine 5'-Triphosphate, an Alternative Substrate Inhibitor of Wild-type and Mutant HIV-1 Reverse Transcriptase: STEADY STATE AND PRE-STEADY STATE KINETIC ANALYSES. J. Biol. Chem. 278: 18971-18979 [Abstract] [Full Text]  
  • Adelson, M. E., Pacchia, A. L., Kaul, M., Rando, R. F., Ron, Y., Peltz, S. W., Dougherty, J. P. (2003). Toward the Development of a Virus-Cell-Based Assay for the Discovery of Novel Compounds against Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 47: 501-508 [Abstract] [Full Text]  
  • Kewn, S., Wang, L. H., Hoggard, P. G., Rousseau, F., Hart, R., MacNeela, J. P., Khoo, S. H., Back, D. J. (2003). Enzymatic Assay for Measurement of Intracellular DXG Triphosphate Concentrations in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrob. Agents Chemother. 47: 255-261 [Abstract] [Full Text]  
  • White, K. L., Margot, N. A., Wrin, T., Petropoulos, C. J., Miller, M. D., Naeger, L. K. (2002). Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity. Antimicrob. Agents Chemother. 46: 3437-3446 [Abstract] [Full Text]  
  • Chin, R., Shaw, T., Torresi, J., Sozzi, V., Trautwein, C., Bock, T., Manns, M., Isom, H., Furman, P., Locarnini, S. (2001). In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to ({-})-{beta}-D-2,6-Diaminopurine Dioxolane and 2'-Fluoro-5-Methyl-{beta}-L-Arabinofuranosyluracil. Antimicrob. Agents Chemother. 45: 2495-2501 [Abstract] [Full Text]  
  • Maga, G., Hübscher, U., Pregnolato, M., Ubiali, D., Gosselin, G., Spadari, S. (2001). Potentiation of Inhibition of Wild-Type and Mutant Human Immunodeficiency Virus Type 1 Reverse Transcriptases by Combinations of Nonnucleoside Inhibitors and D- and L-({beta})-Dideoxynucleoside Triphosphate Analogs. Antimicrob. Agents Chemother. 45: 1192-1200 [Abstract] [Full Text]  
  • Furman, P. A., Jeffrey, J., Kiefer, L. L., Feng, J. Y., Anderson, K. S., Borroto-Esoda, K., Hill, E., Copeland, W. C., Chu, C. K., Sommadossi, J.-P., Liberman, I., Schinazi, R. F., Painter, G. R. (2001). Mechanism of Action of 1-{beta}-D-2,6-Diaminopurine Dioxolane, a Prodrug of the Human Immunodeficiency Virus Type 1 Inhibitor 1-{beta}-D-Dioxolane Guanosine. Antimicrob. Agents Chemother. 45: 158-165 [Abstract] [Full Text]  
  • Bazmi, H. Z., Hammond, J. L., Cavalcanti, S. C. H., Chu, C. K., Schinazi, R. F., Mellors, J. W. (2000). In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (-)-beta -D-Dioxolane-Guanosine and Suppress Resistance to 3'-Azido-3'-Deoxythymidine. Antimicrob. Agents Chemother. 44: 1783-1788 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»